Abstract
Our previous studies demonstrated that a low concentration of 2-methoxyestradiol (2ME2) could induce the differentiation of myeloma cell lines and CD138+ primary myeloma cells from myeloma patients and up-regulate the expression of messenger RNA (mRNA) and protein for the gene encoding X-box binding protein 1 (Xbp-1) in myeloma cell lines. In the present study, we used phosphorothioated antisense oligodeoxynucleotides (ASODN) to investigate the roles and interactions of transcription factors Xbp-1, B-lymphocyte induced maturation protein 1 (Blimp-1), and PAX-5-encoded B-cell-specific activator protein (BSAP), which are thought to be involved in the regulation of B-lymphocytic or plasmacytic differentiation. Blimp-1 ASODN and Xbp-1 ASODN clearly inhibited myeloma cell differentiation and significantly partially inhibited the differentiation effects induced by 2ME2 at low concentration, whereas PAX-5 ASODN clearly induced myeloma cell differentiation and significantly enhanced 2ME2-induced differentiation effects. Moreover, after incubation with Blimp-1 ASODN, the level of Xbp-1 mRNA clearly declined, whereas the level of PAX-5 mRNA significantly increased in myeloma cells. These results demonstrate that transcription factors Xbp-1, Blimp-1, and PAX-5-encoded BSAP play important roles in the regulation of plasmacytic differentiation and exert their effects on differentiation induced by low 2ME2 concentrations. Our primary study provided the rationale for a promising strategy-the future application of transcription-factor ASODN for clinical patients.
MeSH terms
-
2-Methoxyestradiol
-
Cell Differentiation / drug effects*
-
Cell Differentiation / genetics
-
Cell Line, Tumor
-
DNA-Binding Proteins / antagonists & inhibitors
-
DNA-Binding Proteins / genetics
-
DNA-Binding Proteins / metabolism*
-
Dose-Response Relationship, Drug
-
Estradiol / analogs & derivatives*
-
Estradiol / pharmacology
-
Gene Expression Regulation, Neoplastic / drug effects
-
Humans
-
Multiple Myeloma / drug therapy
-
Multiple Myeloma / genetics
-
Multiple Myeloma / metabolism*
-
Multiple Myeloma / pathology
-
Nuclear Proteins / antagonists & inhibitors
-
Nuclear Proteins / genetics
-
Nuclear Proteins / metabolism*
-
Oligodeoxyribonucleotides, Antisense / genetics
-
Oligodeoxyribonucleotides, Antisense / pharmacology
-
Oligodeoxyribonucleotides, Antisense / therapeutic use
-
PAX5 Transcription Factor / antagonists & inhibitors
-
PAX5 Transcription Factor / genetics
-
PAX5 Transcription Factor / metabolism*
-
Plasma Cells / metabolism*
-
Plasma Cells / pathology
-
Positive Regulatory Domain I-Binding Factor 1
-
Regulatory Factor X Transcription Factors
-
Repressor Proteins / antagonists & inhibitors
-
Repressor Proteins / genetics
-
Repressor Proteins / metabolism*
-
Syndecan-1 / genetics
-
Syndecan-1 / metabolism
-
Transcription Factors / antagonists & inhibitors
-
Transcription Factors / genetics
-
Transcription Factors / metabolism*
-
Tubulin Modulators / pharmacology*
-
Up-Regulation / drug effects
-
X-Box Binding Protein 1
Substances
-
DNA-Binding Proteins
-
Nuclear Proteins
-
Oligodeoxyribonucleotides, Antisense
-
PAX5 Transcription Factor
-
PAX5 protein, human
-
Regulatory Factor X Transcription Factors
-
Repressor Proteins
-
SDC1 protein, human
-
Syndecan-1
-
Transcription Factors
-
Tubulin Modulators
-
X-Box Binding Protein 1
-
XBP1 protein, human
-
PRDM1 protein, human
-
Estradiol
-
2-Methoxyestradiol
-
Positive Regulatory Domain I-Binding Factor 1